NCT06260943 Targeted Navigation in Hepatocellular Carcinoma (HCC)
| NCT ID | NCT06260943 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Miami |
| Condition | Hepatocellular Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 210 participants |
| Start Date | 2024-04-15 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 210 participants in total. It began in 2024-04-15 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators are trying to learn more about the personal perceptions and experiences regarding the needs of patients with liver cancer to help improve the care of all patients. The investigators would like to know whether there are needs that patients have or are aware of, especially those needs that the investigators have not been able to address. The investigators aim to develop a program that helps participants and participant's families to navigate the process of being diagnosed with liver cancer and receiving treatment.
Eligibility Criteria
Inclusion Criteria: * HCC Patients: * Enrolled or eligible for enrollment in Unified Prospective Registry and Biorepository of Patients with Chronic Liver Disease or Hepatobiliary Cancers Including Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma. * Diagnosis of hepatocellular carcinoma, confirmed by clinical chart review and International Classification of Diseases, Tenth Revision (ICD-10) C22.0. * Adults, age 18 or older * Able to provide informed consent * All other interviewees: * Advocates who will self-identify as having had HCC. * Others who self-identify as either a caregiver or support person of an HCC patient. Physicians/Licensed Independent Practitioners, Social Workers, Nurse Navigators, and Research Coordinators will all self-identify as being involved in the care of HCC patients. Exclusion Criteria: * Unable to speak Spanish or English * West Haven Grade 2 or higher hepatic encephalopathy19 or other cognitive impairment. * Adults unable or unwilling to consent * Individuals who are not yet adults (infants, children, teenagers) * Prisoners * Given that this study is minimal risk and there are no risks to a potential fetus, investigators will not exclude pregnant women; however, no data about pregnancy or their fetus is being collected
Contact & Investigator
Patricia Jones, MD
PRINCIPAL INVESTIGATOR
University of Miami
Frequently Asked Questions
Who can join the NCT06260943 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06260943 currently recruiting?
Yes, NCT06260943 is actively recruiting participants. Contact the research team at gef44@med.miami.edu for enrollment information.
Where is the NCT06260943 trial being conducted?
This trial is being conducted at Miami, United States.
Who is sponsoring the NCT06260943 clinical trial?
NCT06260943 is sponsored by University of Miami. The principal investigator is Patricia Jones, MD at University of Miami. The trial plans to enroll 210 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.